The industry might agree to savings in 2020 to bolster those negotiated in 2017, only to confront a new round of requests in 2022 or 2023. Any extension in 2020 will mean the industry just pays again for the 'certainty' it already has until mid-2022. …
The price of paying twice or three times for the same 'certainty'
September 14, 2020 CommentLatest News
Latest Video
Georgia Forrest
New Stories
-
Reform was justified because a committee prioritising clinical considerations was 'culturally' problematic
January 4, 2026 - - Latest News -
AdAlta and SHcell launch cancer collaboration to progress breakthrough CAR-T therapy
January 2, 2026 - - Australian Biotech -
Cabinet documents from the year that led to transformational changes
January 1, 2026 - - Latest News -
US pricing push gets real with Australia included in comparison list
December 22, 2025 - - Latest News -
Parsimony has unfortunately become an enduring test of the institution's legitimacy
December 20, 2025 - - Latest News -
PBAC delivers a broad range of outcomes in November, including for obesity
December 20, 2025 - - Latest News -
Takeda’s next-generation psoriasis therapy delivers landmark Phase 3 results
December 19, 2025 - - Latest News